AZN
Price
$69.85
Change
-$0.22 (-0.31%)
Updated
Jun 27 closing price
Capitalization
208.98B
30 days until earnings call
GSK
Price
$38.58
Change
+$0.03 (+0.08%)
Updated
Jun 27 closing price
Capitalization
88.13B
31 days until earnings call
Interact to see
Advertisement

AZN vs GSK

Header iconAZN vs GSK Comparison
Open Charts AZN vs GSKBanner chart's image
AstraZeneca
Price$69.85
Change-$0.22 (-0.31%)
Volume$3.13M
Capitalization208.98B
GSK
Price$38.58
Change+$0.03 (+0.08%)
Volume$4.92M
Capitalization88.13B
AZN vs GSK Comparison Chart in %
Loading...
AZN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AZN vs. GSK commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZN is a Buy and GSK is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (AZN: $69.85 vs. GSK: $38.58)
Brand notoriety: AZN: Notable vs. GSK: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AZN: 69% vs. GSK: 98%
Market capitalization -- AZN: $208.98B vs. GSK: $88.13B
AZN [@Pharmaceuticals: Major] is valued at $208.98B. GSK’s [@Pharmaceuticals: Major] market capitalization is $88.13B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AZN’s FA Score shows that 1 FA rating(s) are green whileGSK’s FA Score has 2 green FA rating(s).

  • AZN’s FA Score: 1 green, 4 red.
  • GSK’s FA Score: 2 green, 3 red.
According to our system of comparison, both AZN and GSK are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AZN’s TA Score shows that 4 TA indicator(s) are bullish while GSK’s TA Score has 5 bullish TA indicator(s).

  • AZN’s TA Score: 4 bullish, 6 bearish.
  • GSK’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, GSK is a better buy in the short-term than AZN.

Price Growth

AZN (@Pharmaceuticals: Major) experienced а -0.14% price change this week, while GSK (@Pharmaceuticals: Major) price change was +1.42% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.72%. For the same industry, the average monthly price growth was +3.48%, and the average quarterly price growth was +7.77%.

Reported Earning Dates

AZN is expected to report earnings on Jul 29, 2025.

GSK is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+0.72% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AZN($209B) has a higher market cap than GSK($88.1B). AZN has higher P/E ratio than GSK: AZN (35.30) vs GSK (14.01). GSK YTD gains are higher at: 16.657 vs. AZN (8.131). AZN has higher annual earnings (EBITDA): 13.4B vs. GSK (9.08B). AZN has more cash in the bank: 5.86B vs. GSK (4.99B). GSK has less debt than AZN: GSK (18B) vs AZN (28.6B). AZN has higher revenues than GSK: AZN (45.8B) vs GSK (30.3B).
AZNGSKAZN / GSK
Capitalization209B88.1B237%
EBITDA13.4B9.08B148%
Gain YTD8.13116.65749%
P/E Ratio35.3014.01252%
Revenue45.8B30.3B151%
Total Cash5.86B4.99B117%
Total Debt28.6B18B159%
FUNDAMENTALS RATINGS
AZN vs GSK: Fundamental Ratings
AZN
GSK
OUTLOOK RATING
1..100
6078
VALUATION
overvalued / fair valued / undervalued
1..100
24
Undervalued
9
Undervalued
PROFIT vs RISK RATING
1..100
4570
SMR RATING
1..100
4641
PRICE GROWTH RATING
1..100
5953
P/E GROWTH RATING
1..100
8420
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GSK's Valuation (9) in the Pharmaceuticals Major industry is in the same range as AZN (24). This means that GSK’s stock grew similarly to AZN’s over the last 12 months.

AZN's Profit vs Risk Rating (45) in the Pharmaceuticals Major industry is in the same range as GSK (70). This means that AZN’s stock grew similarly to GSK’s over the last 12 months.

GSK's SMR Rating (41) in the Pharmaceuticals Major industry is in the same range as AZN (46). This means that GSK’s stock grew similarly to AZN’s over the last 12 months.

GSK's Price Growth Rating (53) in the Pharmaceuticals Major industry is in the same range as AZN (59). This means that GSK’s stock grew similarly to AZN’s over the last 12 months.

GSK's P/E Growth Rating (20) in the Pharmaceuticals Major industry is somewhat better than the same rating for AZN (84). This means that GSK’s stock grew somewhat faster than AZN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AZNGSK
RSI
ODDS (%)
Bearish Trend 3 days ago
47%
Bearish Trend 3 days ago
49%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
65%
Bullish Trend 3 days ago
51%
Momentum
ODDS (%)
Bearish Trend 3 days ago
52%
Bearish Trend 3 days ago
51%
MACD
ODDS (%)
Bearish Trend 3 days ago
42%
Bearish Trend 3 days ago
48%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
46%
Bullish Trend 3 days ago
59%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
45%
Bearish Trend 3 days ago
51%
Advances
ODDS (%)
Bullish Trend 20 days ago
54%
Bullish Trend 3 days ago
58%
Declines
ODDS (%)
Bearish Trend 10 days ago
45%
Bearish Trend 10 days ago
53%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
40%
Bullish Trend 3 days ago
60%
Aroon
ODDS (%)
Bullish Trend 3 days ago
51%
Bullish Trend 3 days ago
45%
View a ticker or compare two or three
Interact to see
Advertisement
AZN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
DYDX.X0.5020770.015051
+3.09%
dYdX cryptocurrency
FEDM55.301.00
+1.84%
FlexShares ESG&Clmt Dev Mkts ex-US Cr
ADVE35.870.42
+1.17%
Matthews Asia Dividend Active ETF
OUSM43.23-0.01
-0.02%
ALPS O'Shares US Sm-Cp Qul Div ETF
FTXO32.86-0.14
-0.42%
First Trust Nasdaq Bank ETF

AZN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AZN has been loosely correlated with NVS. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if AZN jumps, then NVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AZN
1D Price
Change %
AZN100%
-0.31%
NVS - AZN
63%
Loosely correlated
-0.26%
GSK - AZN
59%
Loosely correlated
+0.08%
PFE - AZN
47%
Loosely correlated
-0.21%
LLY - AZN
46%
Loosely correlated
-2.47%
SNY - AZN
45%
Loosely correlated
-1.08%
More

GSK and

Correlation & Price change

A.I.dvisor indicates that over the last year, GSK has been loosely correlated with PFE. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GSK
1D Price
Change %
GSK100%
+0.08%
PFE - GSK
60%
Loosely correlated
-0.21%
AZN - GSK
59%
Loosely correlated
-0.31%
SNY - GSK
52%
Loosely correlated
-1.08%
JNJ - GSK
52%
Loosely correlated
+0.26%
NVS - GSK
44%
Loosely correlated
-0.26%
More